Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
120,192,308
-
Total 13F shares
-
15,624,060
-
Share change
-
-1,222,064
-
Total reported value
-
$62,031,877
-
Put/Call ratio
-
117%
-
Price per share
-
$3.97
-
Number of holders
-
56
-
Value change
-
-$6,395,474
-
Number of buys
-
29
-
Number of sells
-
45
Institutional Holders of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) as of Q2 2021
As of 30 Jun 2021,
Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) was held by
56 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
15,624,060 shares.
The largest 10 holders included
Bratton Capital Management, L.P., VANGUARD GROUP INC, MORGAN STANLEY, MILLENNIUM MANAGEMENT LLC, Bracebridge Capital, LLC, BlackRock Inc., RENAISSANCE TECHNOLOGIES LLC, Latash Investments, LLC, GEODE CAPITAL MANAGEMENT, LLC, and CAAS CAPITAL MANAGEMENT LP.
This page lists
56
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.